MOR202
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glomerulonephritis
Conditions
Glomerulonephritis, Membranous Nephropathy, antiPLA2R Positive
Trial Timeline
Jan 20, 2021 → Dec 14, 2023
NCT ID
NCT04733040About MOR202
MOR202 is a phase 2 stage product being developed by Biogen for Glomerulonephritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04733040. Target conditions include Glomerulonephritis, Membranous Nephropathy, antiPLA2R Positive.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04733040 | Phase 2 | Completed |
| NCT04145440 | Phase 1/2 | Completed |
Competing Products
8 competing products in Glomerulonephritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olmesartan medoxomil | Daiichi Sankyo | Phase 2 | 52 |
| infusion of ADR-001 (Mesenchymal stem cell) | Rohto Pharmaceutical | Phase 1 | 33 |
| Iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| mycophenolate mofetil orally 1000 mg twice a day (BID) + prednisone 0,5 mg/kg orally on alternate days + intravenous (i.v.) methylprednisolone 1000 mg, total 9 | Roche | Phase 2/3 | 65 |
| ACE inhibitor + statin + Sirolimus (study drug)+ACE inhibitor + statin | Pfizer | Phase 2 | 51 |
| Ramipril | Sanofi | Phase 3 | 76 |
| MOR202 | Biogen | Phase 1/2 | 38 |